Published through 2026-11-03 09:41 UTC · Automated cloud publishing.
Ocuco Announces Minority Investment in Ocumetra to Integrate Myopia Analytics
Understand the event
On October 9, 2026, Ocuco announced a minority investment in Ocumetra, a data science company specializing in eyecare. This strategic move aims to integrate Ocumetra’s machine learning tools directly into Ocuco’s practice management software, enhancing capabilities for myopia analytics within clinical workflows. As part of the investment agreement, Leo Mac Canna, the CEO of Ocuco, has joined the board of directors at Ocumetra. The collaboration signifies a deeper integration between Ocuco’s existing software infrastructure and Ocumetra’s advanced data science solutions, specifically targeting improvements in myopia management through automated analytics. The announcement highlights the intent to leverage Ocumetra’s specialized algorithms to support eyecare professionals by embedding these insights into their daily operational tools. No further details regarding the financial terms of the investment or specific implementation timelines were provided in the initial report.
AI-generated from reporting · updated 24 days ago
Reporting timeline
Follow the reporting for different perspectives.
- OcucoOcuco Invests in Ocumetra to Integrate Myopia Analytics into Practice Management Software
Ocuco announced a minority investment in Ocumetra, a data science company for eyecare. As part of the deal, Ocuco CEO Leo Mac Canna joined Ocumetra’s board, and Ocumetra’s machine learning tools will integrate with Ocuco’s next-generation cloud-hosted Practice Management Software. Ocumetra offers nine clinical tools, including the Refractogram for myopia treatment efficacy analytics. Founded in 2020 by Professors James Loughman and Ian Flitcroft, the company aims to support eye care professionals with evidence-based decision tools derived from over one million eyes globally. While some products were slated for early 2022 launch, others are classified as software-as-a-medical-device, requiring regulatory approvals such as ISO13485, CE mark, and FDA clearance.